086060 — Genebiotech Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapValue Trap

Annual cashflow statement for Genebiotech Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-3,432	-484	1,523	2,591	2,865
Depreciation
Amortisation
Deferred Taxes
Non-Cash Items	4,069	452	135	1,459	857
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-69.1	-4,053	-6,624	1,980	-5,554
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	2,492	-2,841	-3,679	7,369	-464
Capital Expenditures	-4,395	-3,115	-1,174	-767	-1,183
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	3,691	9,025	1,824	-4,559	153
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-704	5,910	650	-5,326	-1,030
Financing Cash Flow Items	-94.1	-3,247	—	—	—
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	1,406	-4,490	3,035	-713	2,976
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	3,170	-1,364	-0.077	1,321	1,529